Gainers

• Impact BioMedical (AMEX:IBO) shares rose 70.2% to $0.7 during Thursday's pre-market session. The company's market cap stands at $5.0 million.
• BioXcel Therapeutics (NASDAQ:BTAI) shares moved upwards by 16.96% to $1.93. The company's market cap stands at $36.0 million.
• Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 13.94% to $0.12. The market value of their outstanding shares is at $5.7 million.
• Organigram Global (NASDAQ:OGI) shares increased by 13.66% to $1.58. The company's market cap stands at $187.8 million.
• Aditxt (NASDAQ:ADTX) stock moved upwards by 11.35% to $0.53.
• Veeva Systems (NYSE:VEEV) shares increased by 10.14% to $207.6. The company's market cap stands at $30.9 billion. As per the news, the Q4 earnings report came out yesterday.

Losers

• PepGen (NASDAQ:PEPG) stock declined by 21.6% to $5.3 during Thursday's pre-market session. The market value of their outstanding shares is at $464.7 million. As per the news, the Q4 earnings report came out yesterday.
• Can Fite Biopharma (AMEX:CANF) stock decreased by 14.12% to $5.17. The market value of their outstanding shares is at $7.8 million.
• Firefly Neuroscience (NASDAQ:AIFF) shares declined by 10.97% to $1.38. The market value of their outstanding shares is at $22.0 million.
• Agape ATP (NASDAQ:ATPC) shares decreased by 10.0% to $1.8. The company's market cap stands at $2.0 million.
• Nanoviricides (AMEX:NNVC) stock decreased by 7.97% to $0.88. The market value of their outstanding shares is at $20.6 million.
• Advanced Biomed (NASDAQ:ADVB) shares declined by 6.98% to $4.27. The market value of their outstanding shares is at $6.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.